How Enclomiphene Affects FSH

When enclomiphene blocks estrogen receptors at the anterior pituitary, both LH and FSH secretion increase because the negative feedback signal is removed from both gonadotropin-producing cell types. FSH acts on testicular Sertoli cells, which support spermatid maturation and maintain the blood-testis barrier. Without FSH stimulation, spermatogenesis is severely impaired even when intratesticular testosterone is maintained (as with HCG monotherapy). This is the fundamental mechanistic advantage of SERM-based fertility approaches over HCG alone: SERMs stimulate both branches of the gonadotropin axis simultaneously. In phase 3 trials of enclomiphene (Kaminetsky et al., 2013), men receiving 25 mg/day maintained sperm concentrations of 75-334 million/mL and normal sperm motility throughout the 6-month study period.

At 12.5 mg/day, FSH typically rises 40-70% from baseline within 4 weeks. At 25 mg/day, FSH rises into the upper normal or mildly supranormal range (6-15 IU/L). For men with profoundly suppressed FSH (below 1 IU/L from prior AAS use), response is often slower, requiring 8-12 weeks for FSH to reach levels sufficient for spermatogenesis. A clinically meaningful FSH threshold for spermatogenesis is generally considered 3-5 IU/L; values below this are associated with oligospermia even when testosterone is normal.

Check FSH at baseline and at 6-8 weeks into therapy. For fertility monitoring, FSH is a leading indicator but semen analysis at 3 and 6 months is the true endpoint. Spermatogenesis takes approximately 72 days (one spermatogenic cycle), so FSH-driven improvements in sperm parameters will not appear on semen analysis for at least 3 months after starting enclomiphene. Do not judge fertility outcomes by FSH alone: some men have FSH in normal range but Sertoli cell dysfunction from prolonged AAS use, resulting in poor sperm quality despite adequate gonadotropin stimulation.

Enclomiphene 25 mg/day is the dose with the strongest evidence for FSH restoration in secondary hypogonadal men. If FSH does not rise above 3 IU/L after 8 weeks, consider whether exogenous androgens are still clearing, or whether the duration of prior suppression has caused temporary pituitary unresponsiveness that requires a longer recovery window. Adding HCG to enclomiphene is a recognized combination for severe cases: HCG maintains ITT while enclomiphene drives the FSH component. Monitor estradiol when combining, as both pathways converge on increased aromatization.

Further reading: TRT alternatives: enclomiphene, clomiphene and HCG compared